Diuretic + Arterial Embolization for Liver Cancer

Recruiting at5 trial locations

Overseen by Hooman Yarmohammadi, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.

Research Team

Hooman Yarmohammadi, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with inoperable liver cancer, regardless of viral status. They must have a good performance status (able to carry out daily activities), measurable disease by specific criteria, and be eligible for embolization treatment. People can't join if they're pregnant or breastfeeding, allergic to bumetanide/sulfonamides, have resectable cancer, poor kidney function not on dialysis, certain blood vessel blockages or advanced cirrhosis.

Inclusion Criteria

I am eligible for a procedure to block blood flow to cancer cells.

I have been diagnosed with liver cancer following EASL guidelines.

I have had treatment for my liver before.

Exclusion Criteria

I am at high risk for liver failure after a specific liver procedure due to severe liver disease or extensive liver tumor.

My liver cancer can be surgically removed.

I cannot undergo angiography/embolization due to health issues like severe allergies or poor kidney function.

Treatment Details

Interventions

• Bumetanide (Loop Diuretic)
• Hepatic Artery Embolization (HAE) (Procedure)

Trial Overview The study tests the safety of different doses of Bumetanide when delivered directly into the liver artery followed by plugging up the artery—a procedure known as Hepatic Artery Embolization—to treat liver cancer. The goal is to see how this approach affects patients who are already getting tumor embolization as part of their standard care.

Participant Groups

Group I: Bumetanide Experimental Treatment 2 Interventions

Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University